Regulus Therapeutics Inc. (RGLS) shares gained 15.69% to $1.92 in Monday’s early session after reporting positive clinical trial results. A recent 5-day performance of 24.44% has been achieved by RGLS stock, which gained 5.00% last trading session to finish at $1.68.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RGLS has shared what data?
Today, Regulus Therapeutics (RGLS) announced that its Phase 1 SAD clinical trial of RGLS8429 has shown positive topline safety and PK results. Furthermore, RGLS announced that its Phase 1b MAD clinical trial of RGLS8429 had been initiated.
SAD Phase 1 Study Results Summary
RGLS8429 was found to have favorable safety and PK profile in the Phase 1 SAD study. As far as adverse events were concerned, RGLS8429 was well-tolerated. RGLS8429 or placebo was administered to 32 subjects. Nine adverse events occurred, all of which were mild, with one (sinus infection) graded moderately severe. Plasma levels are dose-proportional across the four dose tests and are similar to first-generation RGLS4326 PK data.
Initiation of Phase 1b of MAD Study
ADPKD patients are enrolled in the phase 1b MAD study under a double-blind, placebo-controlled design.
- In the MAD study, the safety, tolerability, and pharmacokinetics of RGLS8429 will be evaluated.
- The efficacy of RGLS8429 will also be evaluated across three different dose levels, including changes in polycystin levels, cystic kidney volume, and kidney function as a whole.
- Initially, a dose level of 1 mg/kg every other week for three months will be tested in patients with ADPKD.
- It is expected that the first cohort of patients will produce top-line data in the first half of 2023.
How the outcome will help RGLS move further?
The safety and PK data generated in its Phase 1 SAD trial are highly encouraging and allow Regulus Therapeutics (RGLS) the flexibility to use a range of dose levels as RGLS explores the safety and efficacy of RGLS8429 in the Phase 1b MAD study. With the initiation of the MAD study, RGLS anticipates presenting top-line data from the first cohort of patients in the first half of 2023.
